Categorynews

Global Irritable Bowel Syndrome Market to Grow by $779.89 Million Through 2025 – ResearchAndMarkets.com

October 10, 2022 Off By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Global Irritable Bowel Syndrome Market 2021-2025” report has been added to ResearchAndMarkets.com’s offering.

The irritable bowel syndrome market is poised to grow by $779.89 mn during 2021-2025, progressing at a CAGR of 10.09% during the forecast period. The report on the irritable bowel syndrome market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by unhealthy lifestyle habits and increasing incidence of gastrointestinal disorders.

The irritable bowel syndrome market analysis includes the type segment and geographic landscape.

The irritable bowel syndrome market is segmented as below:

By Type

  • IBS-D
  • IBS-C
  • IBS-M

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the increasing awareness of irritable bowel syndrome as one of the prime reasons driving the irritable bowel syndrome market growth during the next few years.

The report on irritable bowel syndrome market covers the following areas:

  • Irritable bowel syndrome market sizing
  • Irritable bowel syndrome market forecast
  • Irritable bowel syndrome market industry analysis

Key Topics Covered:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Type

Market Segmentation by Drug type

Customer landscape

Geographic Landscape

Vendor Landscape

Vendor Analysis

Appendix

Companies Mentioned

  • AbbVie Inc.
  • Alfasigma Spa
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bausch Health Companies Inc.
  • Ironwood Pharmaceuticals Inc.
  • Mallinckrodt Plc
  • Novartis AG
  • Sebela Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/7jy60w

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900